↓ Skip to main content

Cerebral folate receptor autoantibodies in autism spectrum disorder

Overview of attention for article published in Molecular Psychiatry, January 2012
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news
1 news outlet
blogs
2 blogs
twitter
104 X users
patent
3 patents
facebook
16 Facebook pages
wikipedia
6 Wikipedia pages
googleplus
2 Google+ users
reddit
1 Redditor
pinterest
1 Pinner
video
1 YouTube creator

Citations

dimensions_citation
195 Dimensions

Readers on

mendeley
247 Mendeley
Title
Cerebral folate receptor autoantibodies in autism spectrum disorder
Published in
Molecular Psychiatry, January 2012
DOI 10.1038/mp.2011.175
Pubmed ID
Authors

R E Frye, J M Sequeira, E V Quadros, S J James, D A Rossignol

Abstract

Cerebral folate deficiency (CFD) syndrome is a neurodevelopmental disorder typically caused by folate receptor autoantibodies (FRAs) that interfere with folate transport across the blood-brain barrier. Autism spectrum disorders (ASDs) and improvements in ASD symptoms with leucovorin (folinic acid) treatment have been reported in some children with CFD. In children with ASD, the prevalence of FRAs and the response to leucovorin in FRA-positive children has not been systematically investigated. In this study, serum FRA concentrations were measured in 93 children with ASD and a high prevalence (75.3%) of FRAs was found. In 16 children, the concentration of blocking FRA significantly correlated with cerebrospinal fluid 5-methyltetrahydrofolate concentrations, which were below the normative mean in every case. Children with FRAs were treated with oral leucovorin calcium (2 mg kg(-1) per day; maximum 50 mg per day). Treatment response was measured and compared with a wait-list control group. Compared with controls, significantly higher improvement ratings were observed in treated children over a mean period of 4 months in verbal communication, receptive and expressive language, attention and stereotypical behavior. Approximately one-third of treated children demonstrated moderate to much improvement. The incidence of adverse effects was low. This study suggests that FRAs may be important in ASD and that FRA-positive children with ASD may benefit from leucovorin calcium treatment. Given these results, empirical treatment with leucovorin calcium may be a reasonable and non-invasive approach in FRA-positive children with ASD. Additional studies of folate receptor autoimmunity and leucovorin calcium treatment in children with ASD are warranted.

X Demographics

X Demographics

The data shown below were collected from the profiles of 104 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 247 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 4 2%
Australia 1 <1%
United Kingdom 1 <1%
Israel 1 <1%
Japan 1 <1%
Iran, Islamic Republic of 1 <1%
Unknown 238 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 43 17%
Student > Ph. D. Student 30 12%
Student > Master 23 9%
Other 22 9%
Student > Bachelor 22 9%
Other 56 23%
Unknown 51 21%
Readers by discipline Count As %
Medicine and Dentistry 74 30%
Agricultural and Biological Sciences 25 10%
Psychology 20 8%
Biochemistry, Genetics and Molecular Biology 17 7%
Nursing and Health Professions 16 6%
Other 39 16%
Unknown 56 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 109. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 March 2024.
All research outputs
#388,891
of 25,554,853 outputs
Outputs from Molecular Psychiatry
#347
of 4,639 outputs
Outputs of similar age
#1,973
of 249,450 outputs
Outputs of similar age from Molecular Psychiatry
#3
of 35 outputs
Altmetric has tracked 25,554,853 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,639 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 39.6. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 249,450 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.